Abstract: The present disclosure generally relates to methods and compositions for treating subterranean formations. The compositions include a surfactant and may optionally include a solvent. The compositions may also include an additional component, such as a biocide, a scale inhibitor, and/or a corrosion inhibitor. The compositions may be used in methods for enhancing gas lift and increasing hydrocarbon production in subterranean formations.

Abstract: The present invention relates to a method for simulating an application of a make-up product to a body surface. comprising implementing a rendering engine configured to apply a make-up effect comprising at least one colour transformation to at least a portion of incoming image data comprising the body surface to be virtually made-up. and to generate transformed image data simulating said application of make-up product according to at least one colour parameter characteristic of the make-up product to be virtually applied. characterized in that it comprises a prior step of determining said characteristic colour parameter comprising:-acquiring a colour datum of said body surface to be virtually made-up; -acquiring a value of the characteristic colour parameter of the make-up product as a function of said colour data of the body surface to be virtually made-up.

Abstract: In accordance with example embodiments of the invention there is at least a method and apparatus to perform determining, by a network node, context information of a group of more than one user equipment, wherein the context information is based on at least service related information associated with the more than one user equipment; sending information comprising the context information towards at least one base station of a communication network; and based on the context information, negotiating with the at least one base station timing synchronization requirements for distribution to each user equipment of the group.

Abstract: The disclosure relates to an apparatus comprising: means for determining (800) that a relay user equipment associated with the apparatus is unavailable; means for abstaining (802) from attempting any direct network access and/or any indirect network access via another relay user equipment not associated with the apparatus during a time period; and means for attempting (804) at least one indirect network access via the relay user equipment associated with the apparatus during the time period.

Abstract: The present disclosure relates to methods of treating a HR+/HER2? breast cancer in a human subject, wherein the subject has received previously endocrine-based therapy and at least two additional systemic therapies, comprising administering a pharmaceutical composition comprising SG.

Abstract: Embodiments disclosed herein provide a surgical cassette including pump assemblies with improved contact between a displacement sensor disposed within a surgical console and a diaphragm disposed within the surgical cassette. Each pump assembly includes a diaphragm retainer ring that provides a sufficient creepage and clearance margin, acts as a lead-in for the displacement sensor, assists in preventing misalignment, and provides robustness for the ultrasonic welding process which couples the diaphragm retainer ring to the surgical console. The diaphragm retainer ring is impregnated with a lubricant so to facilitate seating of the displacement sensor with the cassette. A cantilever portion of the diaphragm retainer ring increases a creepage and clearance margin, as well as increases overall part strength in the event of a collision with the displacement sensor and during ultrasonic welding. An insulator is also provided that further increases the creepage and clearance margin.

Abstract: Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific irreversible inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.

Abstract: An image sensor includes a photodiode disposed in a semiconductor substrate having a first surface and a second surface opposite to the first surface. A floating diffusion is disposed in the semiconductor substrate. A transfer transistor is configured for coupling the photodiode to the floating diffusion. The transfer transistor includes a vertical transfer gate extending a first depth in a depthwise direction from the first surface into the semiconductor substrate. A transistor is coupled to the floating diffusion. The transistor includes: a planar gate disposed proximate to the first surface of the semiconductor substrate; and a plurality of vertical gate electrodes, each extending a respective depth into the semiconductor substrate from the planar gate in the depthwise direction. The respective depth of at least one of the plurality of vertical gate electrodes is the same as the first depth of the vertical transfer gate.

Abstract: Image sensors, isolation structures, and techniques of fabrication are provided. An image sensor includes a source of electromagnetic radiation disposed on a substrate, a pixel array disposed on the substrate and thermally coupled with source of electromagnetic radiation, and an isolation structure disposed on the substrate between the source of electromagnetic radiation and the pixel array. The isolation structure can define a first reflective surface oriented on a first bias relative to a lateral axis of the pixel array and a second reflective surface oriented on a second bias relative to the lateral axis. The isolation structure can be configured to attenuate residual electromagnetic radiation reaching a proximal region of the pixel array by pairing a first reflection and a second reflection of the electromagnetic radiation by the first reflective surface and the second reflective surface.

Abstract: Disclosed are a microfluidic device and a sample analysis apparatus using the microfluidic device.

Abstract: The present invention encompasses compounds of formula (V) wherein R1a, R1b, R2a, R2b, Z, R4, R5, R14, A, p, X, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

Abstract: There is provided an apparatus comprising: means for determining a communication request associated with relay discovery and selection for a user equipment-to-network, U2N, relay connection establishment for a first user equipment, UE, and means for, based on the communication request, providing, to a U2N relay UE via at least one first user equipment-to-user equipment, U2U, relay UE, the communication request using an established relay chain between the U2N relay UE and a second UE via the at least one first U2U relay UE.

Abstract: Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.

Abstract: A catheter for treating a lesion in a body lumen includes an elongate member, an enclosure, and shock wave emitters enclosed by the enclosure. At least one of the shock wave emitters has a different size than at least one of the other emitters. Providing a smaller shock wave emitter at a distal end of the catheter can help make the catheter more navigable through the body lumen.

Abstract: The present invention encompasses compounds of formula (I), wherein R1a, R1b, R2a, R2b, Z, R3 to R5, A, p, L, U, V and W have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

Abstract: Improved sub-assemblies and methods of control for use in a diagnostic assay system adapted to receive an assay cartridge are provided herein. Such sub-assemblies include: a brushless DC motor, a door opening/closing mechanism and cartridge loading mechanism, a syringe and valve drive mechanism assembly, a sonication horn, a thermal control device and optical detection/excitation device. Such systems can further include a communications unit configured to wirelessly communicate with a mobile device of a user so as to receive a user input relating to functionality of the system with respect to an assay cartridge received therein and relaying a diagnostic result relating to the assay cartridge to the mobile device.

Abstract: Image sensors with improved memory effect are disclosed herein. In one embodiment, a method for reducing image lag associated with a pixel included in a plurality of pixels is described. The pixel includes a photodiode, a first floating diffusion coupled to the photodiode through a transfer transistor, a second floating diffusion coupled to the first floating diffusion through a dual floating diffusion transistor, and a lateral overflow integration capacitor coupled between the second floating diffusion and a bias voltage source. The lateral overflow integration capacitor is further coupled to a pixel reference voltage source through a reset transistor. Operation of the pixel comprises an idle period and an integration period after the idle period. The method also includes configuring the lateral overflow integration capacitor to be either zero-biased or forward-biased during the idle period.

Abstract: A method and a system for performing distance metric learning using proxies are provided. The method for performing distance metric learning assigns a proxy as an anchor to represent a class and associates the proxy with all data points in a training batch. The method allows data points to interact with each other via proxies during training. Additionally, the fine-grained data-to-data relation is actively considered, which is combined with a learnable margin parameter leading to intra-class compactness and inter-class separability.

Abstract: The invention relates to a method for manufacturing a concentrate enriched in iron mineral content from an ore, which contains an iron mineral and silicate, by reverse flotation, which method comprises the step of (c) adding a compound of formula I wherein R1 is C9-C22 alkyl or alkenyl, which is linear or branched, R2 is H, C1-C4 alkyl, which is linear or branched, R3 is —X—NH2, H or C1-C4 alkyl, which is linear or branched, and X is C2-C4 alkylene, which is linear or branched, or a salt of a protonated compound of formula I and an anion, to a prepared aqueous pulp of the ore and optionally one or more flotation auxiliaries to obtain an aqueous mixture. Furthermore, a method for manufacturing a specific group of compounds of formula I, i.e. compounds of formula 1-X wherein R1 is C9-C15 alkyl, which is linear or branched, R2 is H, R3 is —X—NH2 and X is C2-C4 alkylene, which is linear or branched, is disclosed.

Abstract: The present invention provides a catheter for treating occlusions in blood vessels. The catheter includes at least one electrode pair positioned inside of a flexible angioplasty balloon at the distal end of the catheter. In some designs, the electrode pairs are arranged in a low-profile or coplanar configuration, reducing the diameter of the distal end of the device and permitting treatment of tight and hard-to-cross occlusions. The flexible angioplasty balloon has an extremely low profile and does need to be folded before insertion of the catheter into the cardiovascular system. During treatment, the balloon can be expanded a relatively small amount sufficient to immerse the electrode pairs in a conductive fluid before generating shock waves across the electrodes to treat the occlusion. The balloon can be made of material having elastomeric properties such that it returns to its original low profile configuration when it is deflated following treatment.